Beijing Beilu Pharmaceutical Co., Ltd (SHE:300016)

SHE:300016 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	1,049	973.49	884.3	761.45	856.85	826.95
Other Revenue	10.07	10.07	6.42	4.43	3.06	0.39
Revenue	1,059	983.55	890.72	765.88	859.91	827.34
Revenue Growth (YoY)	16.32%	10.42%	16.30%	-10.93%	3.94%	1.00%
Cost of Revenue	586.67	524.59	485.37	365.47	327.99	280.52
Gross Profit	472.06	458.97	405.35	400.41	531.92	546.82
Selling, General & Admin	339.81	332.21	298.78	296.25	363.6	345.85
Research & Development	76.75	69.24	122.33	99.01	47.23	51.72
Other Operating Expenses	6.01	5.22	5.6	11.16	-5	11.61
Operating Expenses	421.54	405.73	430.35	405.53	404.37	409.49
Operating Income	50.52	53.24	-25	-5.12	127.55	137.33
Interest Expense	-59.38	-58.01	-53.14	-47.64	-44.19	-4.84
Interest & Investment Income	13.93	12.73	17.81	8.48	26.32	16.61
Currency Exchange Gain (Loss)	1.18	1.18	-2.76	-1.14	5.31	0.97
Other Non Operating Income (Expenses)	-0.61	-0.74	-0.38	-1.57	-1.84	-1.41
EBT Excluding Unusual Items	5.63	8.4	-63.47	-47	113.15	148.66
Impairment of Goodwill	-	-	-31.82	-	-	-
Gain (Loss) on Sale of Investments	-8.17	-11.95	-13.96	20.54	13.9	19.41
Gain (Loss) on Sale of Assets	-1.33	0.12	0.89	0.1	0.13	-
Asset Writedown	-1.12	-1.14	-1.24	-0.58	-0.76	-4.34
Other Unusual Items	3.92	3.78	8.43	12.17	-4.06	10.11
Pretax Income	-1.07	-0.78	-101.15	-14.76	122.36	173.84
Income Tax Expense	-3.01	-1.05	-17.95	-10.21	12.06	19.84
Earnings From Continuing Operations	1.95	0.27	-83.2	-4.55	110.29	154
Minority Interest in Earnings	14.72	13.38	11.44	15.83	15.22	20.71
Net Income	16.66	13.65	-71.76	11.28	125.51	174.7
Net Income to Common	16.66	13.65	-71.76	11.28	125.51	174.7
Net Income Growth	-	-	-	-91.01%	-28.16%	-48.98%
Shares Outstanding (Basic)	455	455	478	564	483	485
Shares Outstanding (Diluted)	455	455	478	564	483	485
Shares Change (YoY)	-4.80%	-4.88%	-15.21%	16.87%	-0.52%	-0.80%
EPS (Basic)	0.04	0.03	-0.15	0.02	0.26	0.36
EPS (Diluted)	0.04	0.03	-0.15	0.02	0.26	0.36
EPS Growth	-	-	-	-92.31%	-27.78%	-48.57%
Free Cash Flow	48.01	61.63	-86.15	25.03	-39.03	3.9
Free Cash Flow Per Share	0.10	0.14	-0.18	0.04	-0.08	0.01
Dividend Per Share	0.050	0.050	-	0.070	0.070	0.060
Dividend Growth	-	-	-	-	16.67%	-14.29%
Gross Margin	44.59%	46.66%	45.51%	52.28%	61.86%	66.09%
Operating Margin	4.77%	5.41%	-2.81%	-0.67%	14.83%	16.60%
Profit Margin	1.57%	1.39%	-8.06%	1.47%	14.60%	21.12%
Free Cash Flow Margin	4.54%	6.27%	-9.67%	3.27%	-4.54%	0.47%
EBITDA	142.96	143.45	56.28	69.81	190.24	180.04
EBITDA Margin	13.50%	14.59%	6.32%	9.11%	22.12%	21.76%
D&A For EBITDA	92.45	90.21	81.28	74.93	62.7	42.7
EBIT	50.52	53.24	-25	-5.12	127.55	137.33
EBIT Margin	4.77%	5.41%	-2.81%	-0.67%	14.83%	16.60%
Effective Tax Rate	-	-	-	-	9.86%	11.41%
Revenue as Reported	1,059	983.55	890.72	765.88	859.91	827.34

Source: S&P Global Market Intelligence. Standard template. Financial Sources.